AVDL Avadel Pharmaceuticals ADS

Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare Conference

Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare Conference

DUBLIN, April 01, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference on Tuesday, April 8 at 1:30 p.m. ET.

A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel’s Investor Relations website, , for 90 days following the conference.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy. For more information, please visit .

Investor Contact:

Austin Murtagh

Precision AQ



(212) 698-8696

Media Contact:

Lesley Stanley

Real Chemistry



(609) 273-3162



EN
01/04/2025

Underlying

AVDLAvadel Pharmaceuticals ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Avadel Pharmaceuticals ADS

 PRESS RELEASE
Free
AVDL Avadel Pharmace...

Avadel and nference Announce Publication of Real-World Data on Sodium ...

Avadel and nference Announce Publication of Real-World Data on Sodium Oxybate Treatment Patterns in the Journal of Clinical Neuroscience -- Retrospective analysis reveals no significant differences in comorbidities in narcolepsy patients treated vs. not treated with sodium oxybate -- -- One third of patients taking immediate-release, twice-nightly sodium oxybate discontinued treatment, most often due to lack of efficacy; inability to wake up was most common reason for missing second nightly dose -- DUBLIN, April 17, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a b...

April 17, 2025 1 EN
 PRESS RELEASE
Free
AVDL Avadel Pharmace...

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule ...

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, April 10, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to nine (9) new employees to purchase 48,400 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance with Nasdaq Listing Rule...

April 10, 2025 1 EN
 PRESS RELEASE
Free
AVDL Avadel Pharmace...

Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare C...

Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference DUBLIN, April 08, 2025 (GLOBE NEWSWIRE) --  Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today presented at the 24th Annual Needham Virtual Healthcare Conference. The Company provided an update on patient demand metrics that was in line with guidance from its full-year results announcement on March 3, 2025. It also addressed questions related to the recent developments in United States tariff policy and the potential impact on t...

April 8, 2025 1 EN
 PRESS RELEASE
Free
AVDL Avadel Pharmace...

Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcar...

Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare Conference DUBLIN, April 01, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference on Tuesday, April 8 at 1:30 p.m. ET. A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel’s Investor Relations website, , for 90 days following the conference. About Av...

April 1, 2025 1 EN
 PRESS RELEASE
Free
AVDL Avadel Pharmace...

Avadel Announces Publications in CNS Drugs Supplement Highlighting Key...

Avadel Announces Publications in CNS Drugs Supplement Highlighting Key Clinical Issues for People with Narcolepsy and Their Clinicians DUBLIN, March 25, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of six manuscripts covering clinical management, shared decision-making and goal setting for people with narcolepsy and their clinicians in a titled “A New Dawn in the Management of Narcolepsy”. “I am delighted to serve as guest editor for the recently publi...

March 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch